Clinical Trial: Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07840365) titled 'Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion' on Sept. 18.

Brief Summary: Optimal antithrombotic therapy after percutaneous left atrial appendage occlusion (LAAO) to prevent device-related thrombosis (DRT) is not well established. The main aim of improving the drug strategy after appendage closure is to synergistically optimize the device-based thromboembolic (TE) prevention without increasing the risk of thrombus formation on device and bleeding events. Short-term dual antiplatelet therapy (DAPT) followed by long-term aspirin monotherapy is a strategy commonly prescribed after LAA occlu...